Late Failure of Combined Recombinant Hepatitis B Vaccine and Lamivudine in Treatment of a Patient with Chronic Hepatitis B

[Guest guest]

Southern Medical Journal: Volume 97(4) April 2004 pp 407-409

Late Failure of Combined Recombinant Hepatitis B Vaccine and Lamivudine in

Treatment of a Patient with Chronic Hepatitis B

Yalcin, Kendal MD; Degertekin, Halil MD; Bozdayi, Mithat MD, PHD

From the Division of Hepatology, Department of Internal Medicine, Dicle

University School of Medicine, Diyarbakir, and the Institute of Hepatology,

Ankara University School of Medicine, Ankara, Turkey.

Accepted July 9, 2003.

Reprint requests to Kendal Yalcin, MD, Division of Hepatology, Dicle

University School of Medicine, 21280 Diyarbakir, Turkey. Email:

kendaly@...

Abstract

We report the first case of a woman having chronic hepatitis B treated with

a combination therapy of recombinant hepatitis B vaccine and lamivudine for

18 months. The main aims of such a combined therapy were to assess whether

the concomitant anti-hepatitis B virus (HBV) vaccination might prevent the

emergence of a mutant HBV and lead to sustained hepatitis B e antigen

seroconversion with undetectable serum HBV DNA. The data from the present

case demonstrated that combination of anti-HBV vaccine and lamivudine did

not eliminate viral DNA despite prolonged treatment and did not have any

effect on preventing resistant-type HBV. Although the combined therapy

failed to reach the therapeutic endpoints, it concerned a single and unique

patient. Hepatitis B vaccine and lamivudine for HBV treatment should be

further investigated in randomized controlled trials.

[Guest guest]

Southern Medical Journal: Volume 97(4) April 2004 pp 407-409

Late Failure of Combined Recombinant Hepatitis B Vaccine and Lamivudine in

Treatment of a Patient with Chronic Hepatitis B

Yalcin, Kendal MD; Degertekin, Halil MD; Bozdayi, Mithat MD, PHD

From the Division of Hepatology, Department of Internal Medicine, Dicle

University School of Medicine, Diyarbakir, and the Institute of Hepatology,

Ankara University School of Medicine, Ankara, Turkey.

Accepted July 9, 2003.

Reprint requests to Kendal Yalcin, MD, Division of Hepatology, Dicle

University School of Medicine, 21280 Diyarbakir, Turkey. Email:

kendaly@...

Abstract

We report the first case of a woman having chronic hepatitis B treated with

a combination therapy of recombinant hepatitis B vaccine and lamivudine for

18 months. The main aims of such a combined therapy were to assess whether

the concomitant anti-hepatitis B virus (HBV) vaccination might prevent the

emergence of a mutant HBV and lead to sustained hepatitis B e antigen

seroconversion with undetectable serum HBV DNA. The data from the present

case demonstrated that combination of anti-HBV vaccine and lamivudine did

not eliminate viral DNA despite prolonged treatment and did not have any

effect on preventing resistant-type HBV. Although the combined therapy

failed to reach the therapeutic endpoints, it concerned a single and unique

patient. Hepatitis B vaccine and lamivudine for HBV treatment should be

further investigated in randomized controlled trials.

[Guest guest]

Southern Medical Journal: Volume 97(4) April 2004 pp 407-409

Late Failure of Combined Recombinant Hepatitis B Vaccine and Lamivudine in

Treatment of a Patient with Chronic Hepatitis B

Yalcin, Kendal MD; Degertekin, Halil MD; Bozdayi, Mithat MD, PHD

From the Division of Hepatology, Department of Internal Medicine, Dicle

University School of Medicine, Diyarbakir, and the Institute of Hepatology,

Ankara University School of Medicine, Ankara, Turkey.

Accepted July 9, 2003.

Reprint requests to Kendal Yalcin, MD, Division of Hepatology, Dicle

University School of Medicine, 21280 Diyarbakir, Turkey. Email:

kendaly@...

Abstract

We report the first case of a woman having chronic hepatitis B treated with

a combination therapy of recombinant hepatitis B vaccine and lamivudine for

18 months. The main aims of such a combined therapy were to assess whether

the concomitant anti-hepatitis B virus (HBV) vaccination might prevent the

emergence of a mutant HBV and lead to sustained hepatitis B e antigen

seroconversion with undetectable serum HBV DNA. The data from the present

case demonstrated that combination of anti-HBV vaccine and lamivudine did

not eliminate viral DNA despite prolonged treatment and did not have any

effect on preventing resistant-type HBV. Although the combined therapy

failed to reach the therapeutic endpoints, it concerned a single and unique

patient. Hepatitis B vaccine and lamivudine for HBV treatment should be

further investigated in randomized controlled trials.

[Guest guest]

Southern Medical Journal: Volume 97(4) April 2004 pp 407-409

Late Failure of Combined Recombinant Hepatitis B Vaccine and Lamivudine in

Treatment of a Patient with Chronic Hepatitis B

Yalcin, Kendal MD; Degertekin, Halil MD; Bozdayi, Mithat MD, PHD

From the Division of Hepatology, Department of Internal Medicine, Dicle

University School of Medicine, Diyarbakir, and the Institute of Hepatology,

Ankara University School of Medicine, Ankara, Turkey.

Accepted July 9, 2003.

Reprint requests to Kendal Yalcin, MD, Division of Hepatology, Dicle

University School of Medicine, 21280 Diyarbakir, Turkey. Email:

kendaly@...

Abstract

We report the first case of a woman having chronic hepatitis B treated with

a combination therapy of recombinant hepatitis B vaccine and lamivudine for

18 months. The main aims of such a combined therapy were to assess whether

the concomitant anti-hepatitis B virus (HBV) vaccination might prevent the

emergence of a mutant HBV and lead to sustained hepatitis B e antigen

seroconversion with undetectable serum HBV DNA. The data from the present

case demonstrated that combination of anti-HBV vaccine and lamivudine did

not eliminate viral DNA despite prolonged treatment and did not have any

effect on preventing resistant-type HBV. Although the combined therapy

failed to reach the therapeutic endpoints, it concerned a single and unique

patient. Hepatitis B vaccine and lamivudine for HBV treatment should be

further investigated in randomized controlled trials.